Mathew Nagorsky, MD
Otolaryngology · Philadelphia, PANPI 1780655738
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,394 of the $95,211 with a category attached, or 85.5%. Sanofi accounts for 62.4% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $25,830, more than ten times the $523 reported in 2019. Among otolaryngology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 450 payments — averaging $211.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$59K
- Regeneron Healthcare Solutions, Inc.$30K
- Optinose US, Inc.$2K
- GSK$835
- Regeneron$558
- Phathom Pharmaceuticals, Inc.$285
- plus $2K from 26 others
What the payments were for
- Consulting fees$1,1131%
- Speaking & faculty fees$81,39485%
- Travel & lodging$1,3911%
- Food & beverage$11,04512%
- Education$2680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 95 | $59,394 |
| Regeneron Healthcare Solutions, Inc. | 84 | $29,800 |
| Optinose US, Inc. | 127 | $2,168 |
| GSK | 43 | $835 |
| Regeneron | 7 | $558 |
| Phathom Pharmaceuticals, Inc. | 15 | $285 |
| Medtronic | 7 | $275 |
| Alk-abello, Inc | 14 | $260 |
| Stryker | 3 | $185 |
| Inspire Medical Systems, Inc. | 6 | $182 |
| Intersect ENT, Inc. | 4 | $148 |
| Integra Lifesciences Corporation | 2 | $131 |
| Cochlear Americas | 1 | $128 |
| Hikma Pharmaceuticals USA | 8 | $126 |
| Arbor Pharmaceuticals, Inc. | 6 | $92 |
| Aerin Medical Inc. | 5 | $82 |
| Merz North America, Inc. | 3 | $75 |
| Jazz Pharmaceuticals Inc. | 2 | $54 |
| Merz Pharmaceuticals, LLC | 2 | $52 |
| Acclarent, Inc | 2 | $45 |
| Med-el Corporation | 1 | $45 |
| Sanofi-aventis U.S. LLC | 1 | $44 |
| Oticon Medical, LLC | 1 | $39 |
| Merck | 2 | $39 |
| Evoke Pharma, Inc. | 2 | $32 |
| Davol Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Checkpoint Surgical, Inc | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$102,531
- Xhance$243
- SCOPIS ENT$145
- Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode$128
- Baha$128
- OSIA OSI300 IMPLANT$128
- PTeye$120
- NUCALA$102
How this compares
$95,211 in reported general payments places this provider in the 95th percentile of 456 otolaryngology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 33 | $126,277 |
| Dupixent SyringeDupilumab | 14 | $54,064 |
| GimotiMetoclopramide Hcl | 21 | $43,412 |
| XhanceFluticasone Propionate | 47 | $36,420 |
| Fluticasone Propionate | 1,710 | $22,915 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 141 | $17,420 |
| Azelastine Hcl | 749 | $16,466 |
| Fluocinolone Acetonide Oil | 356 | $14,886 |
| RyaltrisOlopatadine Hcl/Mometasone | 57 | $13,186 |
| Dexlansoprazole DrDexlansoprazole | 48 | $12,823 |
| RyventCarbinoxamine Maleate | 27 | $12,014 |
| Omeprazole | 787 | $9,989 |
| Pantoprazole Sodium | 827 | $8,354 |
| QnaslBeclomethasone Dipropionate | 21 | $8,097 |
| Ipratropium Bromide | 279 | $6,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Evoke Pharma, Inc.Gimoti | $32 | $43,41221 claims |
| Optinose US, Inc.Xhance | $2,168 | $36,42047 claims |
| Hikma Pharmaceuticals USARyaltris | $126 | $13,18657 claims |
| MerckJanuvia | $39 | $6,08112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 456 otolaryngology providers in Pennsylvania.
Other otolaryngology in Philadelphia
- Nancy SnydermanPhiladelphia$4.5M
- David KennedyPhiladelphia$603K
- James PalmerPhiladelphia$331K
- Noam CohenPhiladelphia$76K
- Nithin AdappaPhiladelphia$72K
- Steven CannadyPhiladelphia$33K
- David CognettiPhiladelphia$30K
- John KrousePhiladelphia$30K
- Soo AbboudPhiladelphia$23K
- Joseph CurryPhiladelphia$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.